Trial
NCT03290092
Trial of Taselisib in Overgrowth
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Centre Hospitalier Universitaire Dijon
Collaborators
—
Condition
PIK3CA-Related Overgrowth
Intervention
Taselisib (GDC0032)
Why stopped
In accordance with the protocol, following the occurrence of two SUSARs, the TOTEM trial was stopped early for safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-04